About NeuroGT
Developer of gene therapies for rare neurogenetic diseases. It focuses on lysosomal storage disorders and other conditions affecting the central nervous system. The company utilizes advanced gene therapy technologies, including AAV gene replacement therapy and antibody cleaver technology, to target the root causes of these diseases. A key aspect of its approach is a commitment to precision and patient-centric care. Development also includes a scale-up AAV manufacturing platform to support internal development and external partnerships.
- Headquarter Research Triangle Park, United States
- Founders Haiyan Fu
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$456.41 K (USD), Grant
Sep 01, 2024
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of NeuroGT
Investors in NeuroGT
NeuroGT has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for NeuroGT
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NeuroGT
Investment portfolio details for NeuroGT
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NeuroGT
Detailed financials for NeuroGT
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Neurogt Comparisons
Peer comparison for NeuroGT
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NeuroGT
Detailed competitors of NeuroGT
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Neurogt
Complete news archive for NeuroGT
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NeuroGT
NeuroGT was founded in 2019 and raised its 1st funding round 1 year after it was founded.
NeuroGT is headquartered in United States. It is registered at North Carolina, United States.
Rich Giersch is the current CEO of NeuroGT.
Developer of gene therapies for rare neurogenetic diseases. It focuses on lysosomal storage disorders and other conditions affecting the central nervous system. The company utilizes advanced gene therapy technologies, including AAV gene replacement therapy and antibody cleaver technology, to target the root causes of these diseases. A key aspect of its approach is a commitment to precision and patient-centric care. Development also includes a scale-up AAV manufacturing platform to support internal development and external partnerships.
NeuroGT has 1 investor. Key investors include HHS.